Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy

The COVID-19 pandemic has accelerated the development of nucleoside analogs to treat respiratory virus infections, with remdesivir being the first compound to receive worldwide authorization and three other nucleoside analogs (i.e. favipiravir, molnupiravir, and bemnifosbuvir) in the pipeline. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Stevaert, Annelies, Groaz, Elisabetta, Naesens, Lieve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671222/
https://www.ncbi.nlm.nih.gov/pubmed/36403338
http://dx.doi.org/10.1016/j.coviro.2022.101279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671222/
https://www.ncbi.nlm.nih.gov/pubmed/36403338
http://dx.doi.org/10.1016/j.coviro.2022.101279

Ejemplares similares